COMPASS Pathways Plc - American
CMPS
Positions held
Your positionsCMPS isn't in your positions.
Add it to see shares, cost, and P&L here.
Bull / bear case
Site-generated summary from fundamentals, news, and score — not investment advice. As of 2026-10-08.
- COMPASS Pathways is positioned in a growing industry focused on innovative mental health solutions, which could lead to significant market opportunities as demand for mental health care increases.
- The company's target mean price is $23.75, indicating a potential upside from current levels.
- Despite recent challenges, COMPASS has a free cash flow of $249,949,744, providing some financial flexibility.
- COMPASS Pathways has reported consistent net income losses, with a net income of -253.794 million in Q2 2026.
- The company has a strong sell signal with a score of -16.00, indicating negative market sentiment.
- In 2025, COMPASS reported a total revenue of $0.0, highlighting significant operational challenges.
Fundamentals
| Market cap | $1.59B | Enterprise value | $1.21B | Trailing P/E | — | Forward P/E | -8.00 |
| PEG | — | Price / book | 18.41 | Beta | 2.56 | Dividend yield | 0.00% |
| Revenue growth | — | Earnings growth | — | Gross margin | 0.0% | Operating margin | 0.0% |
| Profit margin | 0.0% | ROE | -3.2% | ROA | -29.1% | Debt / equity | 0.65 |
| Current ratio | 1.30 | Free cash flow | $249.95M | Analyst recommendation | strong_buy | Mean target | $23.75 |
| 52w high | $15.87 | 52w low | $4.88 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | |
|---|---|---|---|---|---|
| Revenue | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M |
| Op margin | — | — | — | — | — |
| Net income | -$254M | $91.2M | -$93.9M | -$138M | -$38.4M |
| Gross margin | — | — | — | — | — |
| Gross profit | — | — | — | — | — |
| Operating income | -$49.8M | -$40.4M | -$58.9M | -$36.6M | -$38.6M |
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Revenue | $0.0M | $0.0M | $0.0M | $0.0M |
| Op margin | — | — | — | — |
| Net income | -$288M | -$155M | -$118M | -$91.5M |
| Gross margin | — | — | — | — |
| Gross profit | — | — | — | — |
| Operating income | -$175M | -$157M | -$124M | -$96.0M |
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-10-02 · Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-10-01 · COMPASS Pathways (CMPS) Could Be 49% Below Fair Value Following Its Phase III Progress
2026-09-30 · Compass Pathways Appoints Kelley Boucher as Chief People Officer
2026-09-25 · Compass Pathways Targets Q4 COMP360 NDA Completion, Eyes 2027 Launch
2026-09-24 · Helus Pharma Eyes Q4 Phase III Data for HLP-003 in Major Depression
2026-09-22 · Compass Pathways Targets 2027 COMP360 Launch After Positive Phase III Depression Data
2026-09-22 · Compass Pathways Eyes 2027 COMP360 Launch as FDA Review Advances
2026-09-22 · Cybin Shareholders Weigh Helus Pharma Rebrand, Eight-Member Board
2026-09-22 · Compass Pathways Eyes 2027 COMP360 Launch as FDA Filing Nears
2026-09-21 · Cybin Eyes Q4 Phase 3 Data for Depression Drug HLP003
2026-09-21 · Cybin Eyes Q4 Phase III Depression Readout as Psychedelic Pipeline Advances
Price (daily)
Full chart · RSI · MACD · patterns